Bristol-Myers Announces Updated Findings From Phase 1b Trial
Monday, December 5, 2016
Bristol-Myers Squibb Co. ( BMY ) announced updated findings from the Phase 1b trial, CheckMate -012, in chemotherapy-naÃ¯ve advanced non-small cell lung cancer patients evaluating Opdivo monotherapy, or in combination with Yervoy,at different doses and schedules. Data from this trial have been previously reported. These updated results, with a median follow-up of 16 months, include pooled efficacy findings for the Opdivo and Yervoy combination cohorts(Opdivo 3 mg/kg every two weeks plus Yervoy 1 mg/kg every six [Q6W] or 12 weeks [Q12W]).